Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020

Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States

Manish PatelComments to Author , Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Patel, J. Chen, S. Kim, S. Garg, B. Flannery, C. Reed); Vanderbilt University, Nashville, Tennessee, USA (Z. Haddadin, D. Rankin, N. Halasa, H. Keipp Talbot)

Main Article

Table 1

Conditions and ICD-9-CM and ICD-10-CM codes used to identify enrollees with immunosuppression in MarketScan database, United States, July 2012–August 2017*

Condition ICD-9 codes ICD-10 codes
HIV/AIDS disease
Hematologic malignancy
Lymphatic and hematopoietic tissue malignancy
C81-C83; C88-C96
Other immune conditions‡
Disorders of immune mechanism 279 D89
Neutropenia 288.0 D70
Functional disorders of neutrophils 288.1 D71
Genetic anomalies of leukocytes 288.2 D72.0
Decreased leukocyte count 288.5 D72.81
Leukocyte disease NEC 288.8 D72.89
Leukocyte disease NOS 288.9 D72.9
Myelofibrosis 289.83 D75.81
Blood diseases NEC 289.89 D47.4; D75.89; D75.9; D89.2
Blood diseases NOS 289.9 D75.9; D75.89
Immunologic findings NEC 795.7 R76; R83.4-R87.4; R89.4
Nonspecific immune findings NEC and NOS
R76; R83.4-R87.4; R89.4
Solid malignancy
Organ/system malignant tumors 140–199 C00-C07; C11-C19; C22-C80; Z85
Neuroendocrine tumors 209 C7A; C7B; D3A
Neoplasms of uncertain behavior
Organ transplant§
Complications of transplanted organ 996.8 T86
Organ transplant status
Z94; Z98.85
Sarcoidosis 135 D86
Amyloidosis NOS 277.3 E85
Familial Mediterranean fever 277.31 E85.0; M04
Amyloidosis NEC 277.39 E85.1; E85.3; E85.8
Multiple sclerosis 340 G35
Other CNS demyelination 341 G36; G37.1; G37.3; G37.8; G37.9
Acute infective polyneuritis 357 G61.0; G61.9
Acute myocarditis 422 I40
Polyarteritis nodosa and other 446 M30
Allergic alveolitis/pneumonitis NOS 495.9 T78.40; J67.9
Other alveolar pneumonopathy 516 J84.01; J84.02; J84.09
Enteritis and colitis 555–558 K50-K52
Lupus erythematosus 695.4 L93.0; L93.2; M32
Diffuse connective tissue disease 710 L94; M35.8; M35.9
Arthropathy with infection 711 M12.9; M01.X0; M02.10
Crystal arthropathies 712 M11
Rheumatoid arthritis/inflammatory polyarthropathy 714 M05-M14
Inflammatory spondylopathies 720 M46
Polymyalgia rheumatica 725 M31.5; M35.3

*CNS, central nervous system; ICD9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification; NOS, not otherwise specified; NEC, necrotizing enterocolitis.
†Excludes asymptomatic HIV codes of ICD-9 (V08) and ICD-10 (Z21).
‡Sickle cell disease, asplenia, and psoriatic arthritis were not included in the Greenberg algorithm (20) but are considered to have immune deficiencies by Infectious Diseases Society of America guidelines (5). Adding these to the algorithm only increased the prevalence of immunosuppressive conditions by 0.1%.
§Bone marrow and peripheral stem cell transplant were considered under organ transplant and only considered immunosuppressed if enrollees were currently being given chemotherapeutic agents or immune modulators. Considering these enrollees under other immune conditions in which immunosuppressed does not require receipt of chemotherapeutic agents or immune modulators would increase the overall prevalence of immunosuppressed by 0.01%.
¶Psoriatic arthritis was not included in the Greenberg algorithm and could be an indication for immunosuppressive treatment. Adding this condition did not increase the prevalence of immunosuppressive conditions.

Main Article

Page created: April 29, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.